Grant of Options
January 6, 2021
LONDON, Silence Therapeutics plc, AIM:SLN and NASDAQ: SLN ("Silence" or "the Company") a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that it has granted 580,000 options to Craig Tooman, Chief Financial Officer, under the Silence Therapeutics plc 2018 Employee Long Term Incentive Plan.
Under the grant, 145,000 options will vest on the 12-month anniversary of the award. A further 36,250 share options will vest at the end of each subsequent quarter following the 12- month anniversary for the following 12 quarters. The options will have a strike price of £5.26, the mid-market closing price on AIM on January 5, 2021.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |
| a) | Name | Craig Tooman
|
| 2. | Reason for the notification | |
| a) | Position / status | Chief Financial Officer
|
| b) | Initial notification / Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Silence Therapeutics plc
|
| b) | LEI | 213800SSURRJBX85SQ91
|
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares in Silence Therapeutics plc
ISIN for Silence Therapeutics plc Ordinary Shares: GB00B9GTXM62
|
| b) | Nature of the transaction | Grant of Options under the Silence Therapeutics plc 2018 Employee LTIP Scheme
|
| c) | Prices(a) and volume(s) | 580,000 options with strike price of £5.26 |
| d) | Aggregated information - Aggregated volume - Price |
580,000 £5.26 |
| e) | Date of the transaction | 6 January 2021
|
| f) | Place of the transaction | Outside a trading venue
|
Enquiries:
| Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications ir@silence-therapeutics.com
| Tel: +1 (646) 637-3208 |
| Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence
| Tel: +44 (0) 20 7597 5970 |
| European IR Consilium Strategic Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
| U.S. IR Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
| Tel: +1 (443) 213-0505 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500, a C3 targeting program, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
